Recruitment of clinical research volunteers (breast cancer)
Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.
Research name
This is a phase 3, randomized, open-label study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (MK-2870) followed by carboplatin/paclitaxel compared to chemotherapy (both regimens combined with pembrolizumab) as neoadjuvant treatment for high-risk early-stage triple-negative breast cancer or hormone receptor-weakly positive/HER2-negative breast cancer.
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.
Patients with newly diagnosed, untreated, high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weakly positive/HER2-negative breast cancer. Newly diagnosed, untreated, high-risk early (operable) TNBC or HR-low/HER2-negative breast cancer,
Research remuneration
Related research drugs, designated tests/imaging, and outpatient consultations designated for research are all free of charge. Study-related drugs, specified assessments/imaging, and study-specified clinic visit fees are covered.
Research process
If you are eligible to participate in this study, you will be randomly assigned in a 1:1 ratio to receive either MK-2870 combined with Pembrolizumab followed by standard chemotherapy combined with Pembrolizumab, or standard chemotherapy combined with Pembrolizumab (pre-operatively), followed by surgery and post-operative Pembrolizumab, or Pembrolizumab combined with optional adjuvant therapy.
If eligible, you will be randomized 1:1 to receive MK-2870 plus pembrolizumab followed by standard chemotherapy plus pembrolizumab, or standard chemotherapy plus pembrolizumab (neoadjuvant), then surgery and adjuvant pembrolizumab, or pembrolizumab plus one optional adjuvant therapy.
Related risks
The study drug or procedure may cause mild to moderate discomfort, and the actual experience may vary from person to person; the research team will closely monitor and provide appropriate treatment. Further details can be found in the informed consent form and will be explained by the research physician.
Study drugs/procedures may cause mild-to-moderate discomfort. Actual experience varies. The study team will monitor closely and manage appropriately. Full details are in the informed consent and will be explained by the study physicians.
Contact method
Interested participants can contact us through the following methods for further understanding：
